Chiusura precedente | 27,70 |
Aperto | 29,02 |
Denaro | 27,77 x N/D |
Lettera | 27,91 x N/D |
Min-Max giorno | 29,02 - 29,02 |
Intervallo di 52 settimane | 29,02 - 29,02 |
Volume | |
Media Volume | N/D |
Capitalizzazione | N/D |
Beta (5 anni mensile) | N/D |
Rapporto PE (ttm) | 6,00 |
EPS (ttm) | 4,84 |
Prossima data utili | 03 nov 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include: Two Additional Portfolio Programs (DARE-GML and grant-funded DARE-LBT); License Agreement with Organon to Commercialize XACIATO™; Ovaprene® IDE Approval for Pivotal Contraceptive Efficacy Study; Positive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1 2023 Anticipated Milestones Include: XACIATO First
Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the exclusive license agreement entered into on March 31, 2022 with Organon (NYSE: OGN), a global women’s healthcare company, has become fully effective. Under the agreement, Organon licensed global rights to XACIATO (clindamy